ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

New Lyme guidelines promote options and informed choice

Phases of clinical depression could affect treatment

“Worm pill” could ease autoimmune disease symptoms

Eating Baked or Broiled Fish Weekly Boosts Brain Health, Pitt Study Says

Preserving Cognitive Function with Aging

Scientists Look for Biomarkers to Improve Treatment of Painful Bladder Condition

9 Health Benefits of Cucumbers

New culprit identified in metabolic syndrome

Low vitamin D levels linked to increased risks after noncardiac surgery

Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel

 
Print Page
Email Article

The Open Medicine Institute (OMI) to Develop First-ever Biomarkers for Chronic Fatigue Syndrome and a Range of Complex Diseases

  [ 20 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 29, 2014


The Open Medicine Institute (OMI) to Develop First-ever Biomarkers for Chronic Fatigue Syndrome and a Range of Complex Diseases
Press Release: PR Newswire, May 21, 2014. The Open Medicine Institute (OMI), an organization with a mission to improve health care by applying a multi-disciplinary, "big data" approach, today announced that it will begin development of a biomarker for Chronic Fatigue Syndrome (CFS) and other prevalent, chronic but difficult-to-diagnose diseases.

Plans are in place for development of two key tests - a detection biomarker based on RNA expression data from patients and normal volunteers, and a theranostic tool to evaluate treatment efficacy.  This is especially critical for CFS as there are no proven diagnostics or treatments and many patients and physicians are currently relying on anecdotal efficacy claims of multiple therapies in their efforts to get well.  The proof-of-concept phase of the project has been generously funded by interested Silicon Valley donors and broadly, via the CFS community. 

The novel biomarker project will be led by OMI utilizing Affymetrix' microarray technology and platform.  "With applications and expertise support from Affymetrix, we are looking forward to developing biomarkers for this enigmatic disease that affects over 8 million people globally," said Andreas Kogelnik, MD, Ph.D., Founder of the Open Medicine Institute.  "There is so much misinformation about CFS, we need to focus new tools and technologies on this disease to fully understand and treat it."

Chronic fatigue syndrome is a debilitating and complex disorder characterized by a variety of symptoms including extreme fatigue that is not improved by bed rest and that may be worsened by physical or mental activity. Additional symptoms including exercise intolerance, profound weakness and fatigue, muscle pain and impaired memory typically have severe impacts on a patient's life; in many cases rendering them disabled for years.  Fewer than 20% of individuals will have been diagnosed with CFS and received correct medical attention for this disease.

"Affymetrix is pleased to support OMI on their quest to develop biomarkers for CFS as a model for other chronic diseases – helping to identify difficult to detect conditions and understand and guide treatment decisions," said David Weaver, Chief Commercial Officer at Affymetrix.

OMI will also be utilizing the Affymetrix microarray technology on projects covering other complex diseases such as Autism. 

Expanded Core Affymetrix Facility OMI is now an authorized service provider for Affymetrix.  In this capacity, OMI will provide research services using Affymetrix tools and technologies to those interested in conducting their own studies.  The expanded core facility will also be broadly available to community physicians as a laboratory resource offering research and CLIA-approved testing.


About OMI: OMI is a community-driven organization committed to applying a multi-disciplinary, big data approach to the health care system to advance the understanding of "difficult" diseases and improve patient outcomes.  OMI maintains a clinical research facility based in Mt View, next to El Camino Hospital ("the hospital of Silicon Valley"), including clinical space, laboratory draw station and core genomic/biotechnology laboratory, informatics core, and physiology laboratory.  In addition, OMI interacts with a large network of like-minded international collaborators: solo physicians, academic centers, laboratories, industry, large health systems and others.  OMI has developed and employs a novel technology platform – OpenMedNet – that facilitates information sharing (patient consented and HIPAA compliant) and optimizes collaboration amongst all participants in the health care continuum.   OMI's Board and Advisors include recognized innovators and leaders in the fields of medicine, genomics and technology.  OMI is a California Community Benefits Corporation committed to returning valuable results to the patients and communities it serves.  For more information about the Open Medicine Institute, please visit us here.

Information on Chronic Fatigue Syndrome (ME/CFS): Myalgic Encephalomyelitis Chronic Fatigue Syndrome is a devastating and complex disease affecting neurologic function, metabolism, circulation/blood pressure and overall well being. There are currently over 8 million patients living with ME/CFS worldwide and possibly many more that have gone undiagnosed. ME/CFS can significantly interfere with the patient's daily activities and work.  Patients experience a significantly reduced quality of life – sometimes the mere act of walking across a room has such a profound impact on the cellular-level metabolism that the patient requires days of bed rest thereafter.  ME/CFS has few options for accurate diagnosis and treatment since researchers have not yet identified what causes this disease.  Since there are few effective treatments and no diagnostics, ME/CFS is currently diagnosed only by exclusion.  In the US, the illness is more prevalent than lung cancer, leukemia and AIDS combined. (CDC and SEER Report, 5-year prevalence rates).

SOURCE Open Medicine Institute
 



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance
A Breakthrough for Mitochondrial Dysfunction A Breakthrough for Mitochondrial Dysfunction
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Shoo Pain, Don't Bother Me - Top 10 Nutrients to Take Back Your Life Shoo Pain, Don't Bother Me - Top 10 Nutrients to Take Back Your Life
IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing